Shares of Dyne Therapeutics jumped in afternoon trading and were halted for volatility after Bloomberg reported that the company is considering its options as it receives takeover interest. The developer of drugs to treat muscle diseases has been speaking with advisers about possibilities, including a sale or partnership, people with knowledge of the matter told Bloomberg’s Dinesh Nair and Michelle Davis. Following the report, the shares jumped 8% to $19.40 before being halted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DYN:
- Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Dyne Therapeutics price target lowered to $27 from $29 at Piper Sandler
- Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Dyne Therapeutics 17.15M share Spot Secondary priced at $17.50
- Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
